【摘要】 肺癌是严重威胁人类健康及生命的恶性肿瘤之一,发病率逐年上升,非小细胞肺癌(NSCLC)中Ⅳ期患者可达40%左右。而其中一小部分Ⅳ期NSCLC者呈单脏器孤立转移,且原发灶亦为早期。对此部分患者,其治疗方式同初治时即有多部位远处转移者有所不同;同样,其预后同初治时即有多部位远处转移者亦不相同。对于孤立脑转移患者,在原发NSCLC能够完全切除或已经得到良好控制的情况下,切除同时性或异时性孤立脑转移的5年生存率高达10%～30%,目前的标准治疗推荐手术切除原发灶及孤立脑转移灶或立体定向放疗联合全脑放疗。而孤立肾上腺转移发生率大约在1.62%～3.5%。通过积极的外科切除及联合化疗,NSCLC同时或异时性孤立肾上腺转移患者能延长生存并可获长期生存,5年生存率可达25%～40%。查阅大量相关文献,得出结论认为:对于伴有不同部位的远处孤立转移非小细胞肺癌患者,在原发灶完全切除基础上,进行积极的转移灶局部手术治疗,生存期明显优于其它Ⅳ期患者。更多还原

【Abstract】 Lung cancer is one of the most common tumors which are threatening human lives. About 40% of non-small cell lung cancer (NSCLC) patients were diagnosed at stage Ⅳ. Among these patients, a few presented with early-stage primary lesion accompanied with solitary metastasis in single organ. The management and prognosis of these patients are different from those of patients diagnosed with multiple metastases. For NSCLC with solitary brain metastasis, if the primary tumor has been resected completely or controlled properly, synchronous or heterochronous resection of the solitary brain metastatic focus will raise the 5-year survival rate to 10%-30%. Presently, radical resection of primary and cerebral metastatic tumor or stereotactic radiation combined with whole brain radiotherapy is recommended for such patients. The morbility of solitary adrenal gland metastasis in NSCLC is about 1.62%～3.5%. Radical resection of primary and metastatic tumors combined with chemotherapy could prolong survival of these patients. The 5-year survival rate for these patients could reach 25%～40%. In conclusion, radical resection of the primary and metastatic tumors could prolong the survival of NSCLC patients with solitary metastasis in the brain or adrenal gland or other sites.更多还原